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Background
Over the past few years there has been a remarkable
increase in our knowledge of the variation in human
genome. In parallel genotyping technologies have
advanced significantly and allow sufficient throughput to
accommodate genome-wide approaches. Hyperbilirubi-
nemia is the most common adverse event in patients
treated with atazanavir (ATV). Previous studies showed
that polymorphisms in the uridine-glucuronosyl trans-
ferase (UGT1A1) enzyme and specifically the
UGT1A1*28 variant may influence the risk of hyperbilir-
ubinemia in patients treated with ATV/r.
Purpose of the study
Our objective was to estimate the prevalence of
UGT1A1*28 polymorphism in HIV-infected individuals
in Greece and to determine its potential association
with hyperbilirubinemia in patients receiving boosted
ATV (ATV/r).
Patients and methods
T h ep r e v a l e n c eo ft h eU G T A 1 A 1 * 2 8v a r i a n tw a se s t i -
mated in 80 HIV-infected patients retrospectively, (4/
2009-5/2010) prior to the administration of the first-line
treatment. Wilcoxon rank-sum test was used to deter-
mine whether the total bilirubin levels were different
among carriers and non-carriers of the UGT1A1*28
polymorphism. The presence of the UGT1A1*28 allele
was detected by PCR and DNA electrophoresis.
Results
The UGTA1A1*28 variant was detected in 45 out of 80
individuals (56.25%). Among 55 patients who received
HAART, 20 received ATV/r as part of their first treat-
ment. Of the ATV/r treated patients, 13 were found to
be carriers of the UGT1A1*28 variant (65%). Total bilir-
ubin levels were significantly higher in patients harbour-
ing the UGT1A1*28 polymorphism (median value: 5.15
mg/dl) versus those harbouring the wild type UGT1A1
locus (median value mg/dl: 1.30) (p<0.01). The higher
value of bilirubin was observed at week 4 of treatment
whereas only 3 patients switched ATV/r to other Pro-
tease Inhibitor due to aesthetic problems. Hyperbilirubi-
nemia (total bilirubin >1.3 mg/dl) was not detected in
any patient with the UGT11A1*28 variant receiving any
other therapy than ATV/r based first-line regimens.
Conclusions
Notably, 56% of the HIV-infected patients from a single
HIV Unit in Greece carry at least one copy of the
UGT1A1*28 allele. Carriers of the UGT1A1*28 variant
treated with ATV/r based regimens had significantly
higher levels of total bilirubin than those with UGT1A1
wild type locus, thus, suggesting the clinical utility of
the UGT1A1 testing prior the administration of first-
line treatment.
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